SCPH Logo

scPharmaceuticals Inc. (SCPH) 

NASDAQ
Market Cap
$173.14M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
79 of 774
Rank in Industry
58 of 432

Largest Insider Buys in Sector

SCPH Stock Price History Chart

SCPH Stock Performance

About scPharmaceuticals Inc.

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by …

Insider Activity of scPharmaceuticals Inc.

Over the last 12 months, insiders at scPharmaceuticals Inc. have bought $2M and sold $0 worth of scPharmaceuticals Inc. stock.

On average, over the past 5 years, insiders at scPharmaceuticals Inc. have bought $6.33M and sold $2.34M worth of stock each year.

Highest buying activity among insiders over the last 12 months: ORBIMED ADVISORS LLC (10 percent owner) — $70M.

The last purchase of 500,000 shares for transaction amount of $2M was made by ORBIMED ADVISORS LLC (10 percent owner) on 2024‑08‑13.

List of Insider Buy and Sell Transactions, scPharmaceuticals Inc.

2024-08-13Purchase10 percent owner
500,000
1.2438%
$4.00$2M0.00%
2022-11-25Purchasedirector
762,380
1.7007%
$5.25$4M+1.99%
2022-10-10Saledirector
562,466
1.831%
$4.09$2.3M+91.04%
2022-10-06Saledirector
37,534
0.1225%
$5.02$188,421+56.10%
2022-09-06Sale
6,793
0.022%
$4.75$32,267+43.28%
2022-04-11Sale
220,096
0.776%
$5.00$1.1M+10.62%
2021-12-03PurchasePresident and CEO
10,000
0.0373%
$3.96$39,553+30.15%
2021-12-03Purchasedirector
5,000
0.0184%
$3.91$19,569+30.15%
2021-03-15Sale10 percent owner
110,588
0.3963%
$7.03$777,788-20.33%
2021-03-12Sale10 percent owner
39,469
0.1461%
$7.22$284,816-19.78%
2020-05-26Purchase10 percent owner
578,034
2.5395%
$8.65$5M-12.34%
2020-05-21Purchase10 percent owner
1.39M
6.0411%
$8.65$12M-12.99%
2020-02-14Purchase10 percent owner
271,993
1.2768%
$8.20$2.23M-7.06%
2019-12-13PurchasePresident and CEO
5,000
0.0266%
$5.24$26,189+52.26%
2019-04-11Purchase10 percent owner
389,862
2.1623%
$2.70$1.05M+109.92%
2017-11-21Purchase10 percent owner
833,333
9.7286%
$14.00$11.67M-28.96%
2017-11-21Purchase10 percent owner
1.31M
15.2879%
$14.00$18.33M-28.96%
2017-11-21Purchase
1.31M
15.2879%
$14.00$18.33M-28.96%
2017-11-21Purchase10 percent owner
1.31M
7.6439%
$7.00$9.17M-28.96%
2017-11-21Purchase10 percent owner
714,286
8.3388%
$14.00$10M-28.96%

Insider Historical Profitability

3.64%
ORBIMED ADVISORS LLC10 percent owner
5806670
11.604%
$3.4640<0.0001%
Lundbeckfond Invest A/S10 percent owner
3183986
6.3629%
$3.4610<0.0001%
Agger Mette Kirstine
3183986
6.3629%
$3.4610<0.0001%
5AM Partners IV, LLC10 percent owner
3123302
6.2416%
$3.4610<0.0001%
RA CAPITAL MANAGEMENT, L.P.10 percent owner
2727446
5.4505%
$3.4622+51.43%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
OrbiMed$27.91M15.425.56M0%+$00.22
Helm Capital Management LLC$17.7M9.783.52M+0.71%+$125,500.000.52
Aigh Capital Management Llc$17.01M9.43.39M+9.09%+$1.42M9.73
BlackRock$9.04M51.8M-3.32%-$310,381.57<0.0001
Luther King Capital Management$7.29M4.031.45M+4.28%+$299,242.210.03
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.